GlassScriptPhysician profile
Sami Bourgeois
NPI 1972928398
$4,495.30
in general payments reported to CMS, 2019-2025
35 companies · $694 in 2025
The $694 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,819 · 2022: $959 · 2023: $455 · 2024: $568 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,143.85 | 2021-2025 | |
| Astellas Pharma US INC | $477.33 | 2021-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $437.89 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $325.17 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $219.72 | 2021-2024 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $196.74 | 2021-2023 | Gardasil 9 |
| Pfizer INC. | $181.99 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.70 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $134.49 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.49 | 2021-2022 | |
| Amarin Pharma, INC. | $121.74 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.55 | 2021-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.45 | 2022-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $78.41 | 2021-2022 | |
| Esperion Therapeutics, INC. | $77.48 | 2023-2025 | Nexletol |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $75.13 | 2022-2025 | |
| Biogen, INC. | $68.64 | 2021 | |
| Axsome Therapeutics, INC. | $66.49 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $64.13 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $43.86 | 2024 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $38.63 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $37.12 | 2025 | Fanapt, Hetlioz |
| Convatec INC. | $29.30 | 2024 | |
| Amgen INC. | $24.20 | 2021 | |
| Ardelyx, INC. | $22.25 | 2025 | Ibsrela |
| Biohaven Pharmaceuticals, INC. | $19.38 | 2021 | |
| Sumitomo Pharma America, INC. | $19.00 | 2024 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $16.58 | 2024 | Austedo Xr |
| Bausch Health US, LLC | $16.22 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.12 | 2022 | |
| Exact Sciences Corporation | $14.87 | 2025 | The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $14.08 | 2023 | Seglentis |
| Adlon Therapeutics L.P. | $13.80 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.33 | 2021 | |
| Corium, LLC | $4.17 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sami Bourgeois listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.